4.4 Article

Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

期刊

JOURNAL OF CLINICAL LIPIDOLOGY
卷 5, 期 3, 页码 133-140

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacl.2011.03.001

关键词

Familial hypercholesterolemia; LDL receptor; Apheresis; Cascade screening; Heterozygous; Heterozygote; Homozygous; Homozygote

资金

  1. Abbott Laboratories
  2. Aegerion Pharmaceuticals
  3. Daiichi Sankyo
  4. Genzyme
  5. Kaneka Pharma America LLC
  6. Merck Co.
  7. American Diabetes Association
  8. American Heart Association
  9. AstraZeneca
  10. Bristol-Myers Squibb
  11. diaDexus
  12. GlaxoSmithKline
  13. Kowa Pharmaceuticals
  14. National Institutes of Health
  15. Novartis
  16. Roche/Genentech
  17. Sanofi-Synthelabo
  18. Takeda Pharmaceuticals
  19. Isis Pharmaceuticals
  20. Amarin
  21. ISIS-Genzyme Corporation
  22. Regeneron
  23. Hoffman LaRoche
  24. Merck Schering Plough
  25. Spirocor
  26. Genzyme Corporation

向作者/读者索取更多资源

The familial hypercholesterolemias (FH) are a group of genetic defects resulting in severe elevations of blood cholesterol levels and increased risk of premature coronary heart disease. FH is among the most commonly occurring congenital metabolic disorders. FH is a treatable disease. Aggressive lipid lowering is necessary to achieve the target LDL cholesterol reduction of at least 50% or more. Even greater target LDL cholesterol reductions may be necessary for FH patients who have other CHD risk factors. Despite the prevalence of this disease and the availability of effective treatment options, FH is both underdiagnosed and undertreated, particularly among children. Deficiencies in the diagnosis and treatment of FH indicate the need for greatly increased awareness and understanding of this disease, both on the part of the public and of healthcare practitioners. This document provides recommendations for the screening, diagnosis and treatment of FH in pediatric and adult patients developed by the National Lipid Association Expert Panel on Familial Hypercholesterolemia. This report goes beyond previously published guidelines by providing specific clinical guidance for the primary care clinician and lipid specialist with the goal of improving care of patients with FH and reducing their elevated risk for CHID. (C) 2011 National Lipid Association. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据